5-ASA use questioned after escalating IBD treatment

The value of continuing 5-aminosalicylic acid treatment is being questioned after a study found little apparent benefit in patients who started anti-TNF and immunosuppressive therapies. Most patients with IBD still receive at least one dispensation of 5-aminosalicylic acid (5-ASA) but their use is dropping, particularly in Crohn’s disease, a Canadian study has shown. A retrospective ...

Already a member?

Login to keep reading.

© 2021 the limbic